The first clinical trial of a gene-editing therapy for human immunodeficiency virus type 1 (HIV) infection is now underway, thanks to a major collaborative effort between scientists at the Lewis Katz School of Medicine and investigators at Excision BioTherapeutics, Inc. The trial, designed to evaluate the safety, tolerability, and efficacy of EBT-101, a unique gene-editing treatment that could alter the future of HIV therapeutics, marks a major step forward in the effort to find a cure for HIV/AIDS.